Thetis Pharmaceuticals to Present New Preclinical and Clinical Data for its BLT1 Agonist TP-317 at the 2025 European Crohn’s and Colitis Organization (ECCO) Annual Meeting
ESSEX, Conn.--(BUSINESSWIRE)—January 7, 2025—Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, today announced its upcoming presentations of new preclinical and clinical data at the 20th Congress of ECCO. The meeting will take place from February 19-22, 2025, in Berlin, Germany.
The data will be featured in poster sessions highlighting the efficacy and mechanism of action of TP-317 in preclinical models of colitis, as well as the pharmacokinetics, pharmacodynamics, and safety profile of oral TP-317 observed in a Phase 1a clinical study involving healthy volunteers.
Details of the data presentations are as follows:
Poster 1:
Title: TP-317, a Novel BLT1 Agonist Oral Therapy for Inflammatory Bowel Disease, Exhibits Anti-Inflammatory and Epithelial Barrier Protective Efficacy in Murine DSS Colitis and TNFΔARE Ileitis (Abstract Number: P0069)
Poster 2:
Title: Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Oral Resolvin E1-based Therapy in Inflammatory Bowel Disease (IBD): Translating Resolvin E1 Activation of BLT1 in Experimental Models to Healthy Volunteers
Abstract Number: P0627
Date and time: Both posters will be presented on Friday, February 21, 2025, 12:40 PM - 1:40 PM CEST (6:40 AM-7:40 AM EST)
Location: Poster Exhibition Hall 2.2, CityCube Messe Berlin, Messedamm 26, 14055 Berlin, Germany
About Thetis Pharmaceuticals
Thetis is a clinical-stage pharmaceutical company focused on developing innovative treatments for chronic inflammatory diseases and cancer. Thetis’ lead candidate, TP-317, is a first-in-class, oral Resolvin E1 (RvE1) drug candidate that targets the LTB4-BLT1 pathway to activate the body’s natural healing mechanisms. In a Phase 1a study, TP-317 was safe, well tolerated, and effectively delivered RvE1 to systemic circulation.
For more information, please visit www.thetispharma.com, and follow us on LinkedIn.
Contact
Tracy Lessor
TLOW Communications, LLC
617-519-9827
tracy@tlowcommunications.com